Drug intelligence / Profile preview

pioglitazone + simvastatin

Development stage: Preclinical
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of pioglitazone, a thiazolidinedione (TZD) antidiabetic medication that improves insulin sensitivity, and simvastatin, an HMG-CoA reductase inhibitor (statin) that lowers cholesterol levels. This combination offers complementary benefits in managing type 2 diabetes with cardiovascular risk factors and non-alcoholic fatty liver disease (NAFLD). The combination demonstrates additive anti-inflammatory effects, complementary lipid management, and metabolic improvements beyond what either medication achieves alone.

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on pioglitazone + simvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pioglitazone + simvastatin.

Explore the full profile